Phase trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer

By      

Molecular and Clinical Oncology, Vol. 3, Iss. 4, 2015-01 ,pp. : 865-868

Science Publishers

Access to resources Recommend Favorite

Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan

By Nishimura Kazuo  

International Journal of Clinical Oncology, Vol. 18, Iss. 2, 2013-04 ,pp. : 306-313

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

By Sridhar Srikala   Canil Christina   Chi Kim   Hotte Sebastien   Ernst Scott   Wang Lisa   Chen Eric   Juhasz Agnes   Yen Yun   Murray Peter   Zwiebel James   Moore Malcolm  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 927-933

Springer Publishing Company

Access to resources Recommend Favorite

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

By Sternberg C. N.   Molina A.   North S.   Mainwaring P.   Fizazi K.   Hao Y.   Rothman M.   Gagnon D. D.   Kheoh T.   Haqq C. M.   Cleeland C.   de Bono J. S.   Scher H. I.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1017-1025

Oxford University Press

Access to resources Recommend Favorite

A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates

By Jochems Caroline   Tucker Jo   Tsang Kwong-Yok   Madan Ravi   Dahut William   Liewehr David   Steinberg Seth   Gulley James   Schlom Jeffrey  

Cancer Immunology, Immunotherapy, Vol. 63, Iss. 4, 2014-04 ,pp. : 407-418

Springer Publishing Company

Access to resources Recommend Favorite